Philippines Seeks to Vaccinate 100 Million Citizens by 2023
(Bloomberg) -- The Philippines targets to vaccinate its entire population of more than 100 million people against the coronavirus by 2023, with President Rodrigo Duterte opting to be given a vaccine either from China or Russia, officials said.
Vaccine rollout may start as early as February, although bulk of the inoculations will begin in the second half of 2021, vaccine czar Carlito Galvez said at a Senate hearing Monday. The capital region, which accounts for more than a third of Covid-19 infections, will be a priority, he said.
The government may sign supply deals this week with vaccine-makers including AstraZeneca Plc. and Sinovac Biotech Ltd. for 60 million doses, he said. A term sheet was signed with Serum Institute of India for 30 million doses, while supply agreements are also being finalized with Pfizer Inc.-BioNTech SE, Johnson & Johnson, Moderna Inc. and Russia's Gamaleya National Center of Epidemiology and Microbiology, Galvez said.
Indonesia to Start Inoculations: Southeast Asia Vaccine Tracker
Sinovac has committed to deliver 25 million vaccine doses to the Philippines this year, presidential spokesman Harry Roque said at a separate briefing, with the first shipment expected in February. Duterte wants to be inoculated as soon as possible, and will only choose from vaccines from China and Russia, Roque said.
Herd immunity may be achieved this year, Health Secretary Francisco Duque said at the Senate hearing, as the government targets to buy 148 million vaccine doses to inoculate more than half of the population in 2021. Some 82.5 billion pesos ($1.7 billion) have been allocated for vaccine purchases this year, bulk of which are from loans.
Safety concerns are discouraging almost half of Philippine citizens to get inoculated, according to a Pulse Asia Research Inc. survey, posing a challenge to the vaccination plan which underpins the nation's economic recovery.
©2021 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.